Automate Your Wheel Strategy on CLDX
With Tiblio's Option Bot, you can configure your own wheel strategy including CLDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLDX
- Rev/Share 0.0872
- Book/Share 9.8718
- PB 2.259
- Debt/Equity 0.0046
- CurrentRatio 19.6707
- ROIC -0.3552
- MktCap 1480864928.0
- FreeCF/Share -2.8174
- PFCF -7.9167
- PE -7.4172
- Debt/Assets 0.0044
- DivYield 0
- ROE -0.2762
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CLDX | Canaccord Genuity | -- | Buy | -- | $64 | April 28, 2025 |
| Initiation | CLDX | Morgan Stanley | -- | Overweight | -- | $46 | March 20, 2025 |
| Initiation | CLDX | UBS | -- | Buy | -- | $44 | Feb. 13, 2025 |
| Initiation | CLDX | Citigroup | -- | Buy | -- | $70 | Oct. 7, 2024 |
| Initiation | CLDX | Goldman | -- | Neutral | -- | $45 | Sept. 30, 2024 |
| Downgrade | CLDX | Wolfe Research | Outperform | Peer Perform | -- | -- | Sept. 27, 2024 |
News
Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track
Published: August 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Celldex Therapeutics, Inc.'s barzolvolimab failed to improve symptoms in eosinophilic esophagitis, but this setback doesn't impact its promising ongoing urticaria programs. Phase 3 trials for chronic spontaneous urticaria are underway, with additional studies for chronic inducible urticaria set to begin soon in 2nd half of 2025. The global urticaria market size is projected to reach $11.4 billion by 2032.
Read More
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors.
Read More
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.57 per share a year ago.
Read More
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
HAMPTON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2024 and provided a corporate update.
Read More
About Celldex Therapeutics, Inc. (CLDX)
- IPO Date 1986-05-15
- Website https://www.celldex.com
- Industry Biotechnology
- CEO Anthony S. Marucci
- Employees 186